✨ 100% Authentic — guaranteed🚚 Free delivery on orders over ৳2,000🇧🇩 Fast delivery across Bangladesh💳 Cash on delivery available🎁 New arrivals every week
Product image 1
Product image 2
Product image 3
Product image 4
Product image 5
Product image 6
Product image 7
Product image 8

medicube TXA Niacinamide Capsule Cream (55g)

No reviews yet
100% Authentic guaranteed✦ Earn 125 points with this product
From BDT 2,500.00
Quantity
1
  • Free shipping on orders over BDT 1,990
  • Estimated delivery by 2–3 days
Need help? Chat with us on WhatsApp
medicube TXA Niacinamide Capsule Cream (55g)
BDT 2,500.00

Medicube TXA Niacinamide Capsule Cream (55 g) is a brightening and spot-correcting moisturizer that helps fade dark spots, acne marks, and uneven tone for luminous, clear skin. Formulated with Tranexamic Acid (TXA) and Niacinamide, this powerful duo targets hyperpigmentation and strengthens the skin barrier for long-lasting radiance. This brightening capsule cream features tiny vitamin capsules that burst upon application, releasing potent active ingredients directly into the skin for maximum absorption. Moreover, TXA helps inhibit melanin production, reducing dark patches and discoloration, while Niacinamide refines pores, controls oil, and improves texture. As a result, your complexion becomes brighter, smoother, and visibly more even. Enriched with Hyaluronic Acid and Ceramides, it locks in moisture and enhances elasticity without greasiness. The lightweight, gel-cream texture glides effortlessly and absorbs fast, making it perfect for daily use in humid weather. With continued use, it visibly fades post-acne pigmentation and dullness for a naturally glowing complexion. Free from parabens, artificial fragrance, and alcohol, this cream is gentle enough for sensitive skin and safe for all skin types. Dermatologically tested and clinically proven to reduce dark spots, it’s an essential K-Beauty product for those seeking radiant, healthy skin in Bangladesh’s tropical climate.

Have questions about the product?

AI answers coming soon — replies are placeholders for now.